ArticleHormones (Athens, Greece)2026
Exogenous parathyroid hormone (1-34) attenuates knee osteoarthritis in mice through activating the TGF-β/Smad signaling pathway.
Article in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveParathyroid hormone (PTH) has been reported to delay the progression of osteoarthritis (OA), while the mechanism remains unclear. The TGF-β/Smad signaling pathway plays a key role in chondrocyte regulation and OA development. We aimed to explore the effect and mechanism of PTH on knee OA (KOA) in mice.
methodsAnterior cruciate ligament transection (ACLT) was performed in 40 mice to induce KOA. They were randomly divided into the ACLT + PTH and ACLT + vehicle groups. Another 20 mice that underwent only arthrotomy and normal saline were allocated to the sham-vehicle group. The knee phenotypes were analyzed using radiograph, micro-CT, and histology. The mRNA and protein expression levels of related factors were detected by immunohistochemistry and qRT-PCR.
resultsPTH (1-34) attenuated knee OA phenotypes induced by ACLT, including reducing the modified Mankin's scores (p = 0.002, 0.001) and OARSI scores (p = 0.06, 0.02), enhancing type II collagen synthesis (p = 0.001, p < 0.001), and inhibiting type X collagen (p = 0.014, 0.011) and MMP-13 expression (p = 0.002, p < 0.001) in articular cartilage of ACLT mice at 2 weeks and 4 weeks. PTH also significantly increased the percentage of parathyroid hormone receptor 1 (PTH1R) (p < 0.001), p-cAMP response element binding protein (p-CREB) (p < 0.001), proliferating cell nuclear antigen (PCNA) (p = 0.011, p < 0.001), TGF-β receptor I (TβRI) (p = 0.002, p < 0.001), TβRII (p < 0.001), Smad2 (p = 0.014, p < 0.001), and p-Smad2/3 positive cells (p < 0.001) in the articular cartilage of ACLT mice. PTH significantly increased mRNA expression levels of PTH1R, p-CREB, PCNA, TβRI, TβRII, and Smad2 in the articular cartilage of ACLT mice (p < 0.001).
conclusionPTH (1-34) attentuates knee OA induced by ACLT by stimulating proliferation, inhibiting hypertrophy and maturation of chondrocytes and the degradation of articular cartilage, and activating the TGF-β/Smad signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.